网传一笔450美元的专利维持费滞纳金,让诺和诺德在加拿大市场提前失去了司美格鲁肽的核心专利保护。这个看似微小的管理疏失,却意外成为了窥视诺和诺德与礼来之间巨大市值鸿沟的一扇窗口。资本市场正以令人瞠目的方式,重新评估全球两大GLP-1巨头。当诺和诺德因一款“减肥神药”风头正劲时,其市值却仅为竞争对手礼来的五分之一。这看似违背直觉的1:5市值比例背后,远不止是两款GLP-1药物的销售竞赛。加拿大专利局...
Source Link网传一笔450美元的专利维持费滞纳金,让诺和诺德在加拿大市场提前失去了司美格鲁肽的核心专利保护。这个看似微小的管理疏失,却意外成为了窥视诺和诺德与礼来之间巨大市值鸿沟的一扇窗口。资本市场正以令人瞠目的方式,重新评估全球两大GLP-1巨头。当诺和诺德因一款“减肥神药”风头正劲时,其市值却仅为竞争对手礼来的五分之一。这看似违背直觉的1:5市值比例背后,远不止是两款GLP-1药物的销售竞赛。加拿大专利局...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.